We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Stuart Gordon

Stuart Gordon MD

Professor of Medicine, Wayne State University School of Medicine, Detroit, Michigan, and Director, Division of Hepatology, Henry Ford Health System, Detroit, Michigan

Dr. Gordon is Professor of Medicine, Wayne State University School of Medicine, Detroit, Michigan and Director, Division of Hepatology, Henry Ford Health System, Detroit, Michigan.  He is a graduate of Wayne State University School of Medicine, Detroit, Michigan (MD) and received his training in clinical hepatology at University of Miami School of Medicine, Miami, Florida.  His major research interests include the epidemiology and treatment of viral hepatitis, and the epidemiology and treatment of cholestatic liver disease. He authored or co-authored over 200 articles, 15 book chapters, 4 invited editorials and 1 textbook. His current H-index is 53. He is identified in the 2018 Highly Cited Researchers list from Clarivate Analytics.  Dr. Gordon has served as an ad-hoc member of several NIH and NCI Study Sections and he is on the editorial board of Clinical Gastroenterology and Hepatology. Dr. Gordon was the recipient of the Distinguished Alumni Award from Wayne State University School of Medicine. He is currently an appointed member of the AASLD-IDSA Hepatitis C Guidance Committee. In collaboration with the Centers for Disease Control, Dr. Gordon is the Principal Investigator of the multicenter CHeCS (Chronic Hepatitis Cohort Study) that examines the health burden, natural history, epidemiology and treatment challenges posed by chronic viral hepatitis in the United States. He is also the Principal Investigator of the Fibrotic Liver Disease (FOLD) consortium of 11 US medical centers that collectively serve 4.2 million patients, and which examines the prevalence, natural history, treatment uptake/response, and clinical outcomes of patients with Primary Biliary Cholangitis (PBC) in the United States.

Disclosures

Dr. Gordon receives research funding (to institution) from Gilead and AbbVie.